Guggenheim analyst Subbu Nambi raised the firm’s price target on Myriad Genetics to $29 from $25 and keeps a Buy rating on the shares following what the firm calls “another solid beat and raise” report. The firm continues to believe the outlook for long-term revenue growth and profitability is attractive, the analyst tells investors post earnings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
- Myriad Genetics appoints Jennifer Fox as CLO
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Myriad Genetics announces results from nationwide Cancer Risk Survey
- What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk